Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.08. | Impact Biomedical announces 3F US patent issue | 1 | Seeking Alpha | ||
18.08. | Impact Biomedical Inc (IBO) Announces 3F US Patent Issue | 134 | GlobeNewswire (Europe) | HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition... ► Artikel lesen | |
14.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
24.06. | DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger | 171 | GlobeNewswire (Europe) | NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management... ► Artikel lesen | |
IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
23.06. | Impact Biomedical-Aktie steigt nach Fusionsvereinbarung mit Dr Ashleys | 11 | Investing.com Deutsch | ||
23.06. | Impact Biomedical stock soars after merger deal with Dr Ashleys | 1 | Investing.com | ||
23.06. | IMPACT BIOMEDICAL INC; Dr Ashleys Limited: Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger | 299 | GlobeNewswire (Europe) | A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical... ► Artikel lesen | |
23.06. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
28.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
21.03. | Impact BioMedical-Aktien steigen bei unerklärlicher Marktaktivität | 8 | Investing.com Deutsch | ||
21.03. | Impact BioMedical shares soar on unexplained market activity | 1 | Investing.com | ||
21.03. | Impact BioMedical-Aktie schwankt ohne erkennbaren Grund | - | Investing.com Deutsch | ||
21.03. | Impact BioMedical shares fluctuate without clear cause | 1 | Investing.com | ||
21.03. | Impact Biomedical Inc. Announcement Stock Activity/Pricing | 270 | GlobeNewswire (Europe) | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 733 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
21.03. | Why Impact Biomedical Inc. (IBO) Surged On Thursday? | 16 | Insider Monkey | ||
13.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 5 | SEC Filings | ||
26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 356 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen | |
15.10.24 | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 239 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
26.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 223 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,05 | +0,05 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
EVOTEC | 5,856 | +2,70 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,890 | +12,68 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,980 | +9,16 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
MINERALYS THERAPEUTICS | 34,750 | +4,92 % | Mineralys reports positive subgroup data for hypertension drug | ||
VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
CG ONCOLOGY | 33,105 | +7,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,090 | -5,61 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
ARCUTIS BIOTHERAPEUTICS | 17,200 | +6,11 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |